Q-omics provides the consensus-scored ZNF607 profile across patient tissues and cancer cell-line models. ZNF607 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZNF607 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, ZNF607 RNA expression shows 20,535 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCS, THCA, and KIRP as cancer lineages where ZNF607 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF607 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF607 survival associations across molecular data types. ZNF607 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF607 RNA expression–survival associations across cancer types. High ZNF607 expression shows unfavorable associations in LGG, CESC and LUAD, but favorable associations in UCS, KIRC and PAAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for ZNF607 RNA expression.
This table summarizes ZNF607 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF607. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF607 shows lower tumor expression in THCA and HNSC and higher tumor expression in COAD, LIHC, LUAD and BRCA. The THCA box plot shows higher ZNF607 RNA expression in normal versus tumor tissue (log2 FC = −0.561, t-test p < 0.001).
This table shows molecular features associated with ZNF607 in patient tissues and cancer cell lines. In patient samples, ZNF607 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF607 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
